1. Perspectives on Managing Polycythemia Vera for the Nurse Practitioner and Physician Assistant

3. Program Objectives

4. Polycythemia Vera Overview

5. Patient Case 1 Initial Presentation

6. When to Suspect PV

7. Initial Workup for PV

8. WHO 2016 Diagnostic Criteria for PV

9. Patient Case 1 (cont)

10. Audience Question 1

11. Risk Stratification for Thrombosis in PV

12. Risk Factors for Decreased Survival in PV

13. Causes of Mortality in Patients With PV

14. PV Treatment Goals

15. Management of Disease Symptoms

16. Communication Between Providers and Patients/Caregivers

17. Communication Among the Healthcare Team

18. Cytoreductive Therapy

19. Symptomatic Profiles of Patients With PV According to HU Use

20. PV Risk-Adapted Treatment Strategy

21. Management of Treatment-Related AEs

22. Patient Case 1 2 Years Later

23. Evaluating Response to Treatment

24. Patient Case 1 Resolution

26. Patient Case 2 Presentation

27. Patient Case 2 (cont)

28. Resistance to or Intolerance of HU or IFNα

29. How to Determine Resistance to or Intolerance of HU

30. Audience Question 2

31. Alternative Therapies for PV Resistant to or Intolerant of HU

32. Pegylated IFNα2a for PV Phase 2 Study Responses

33. Pegylated IFNα2a for PV Molecular Response

34. Ruxolitinib

35. Mechanism of JAK-STAT Signaling

36. Ruxolitinib for PV Phase 3 RESPONSE Trial

37. RESPONSE Trial Efficacy Results

38. Ruxolitinib Dosing in PV

39. Ruxolitinib Dose Modifications

40. Ruxolitinib Safety Profile

41. Management of AEs

42. Patient Case 2 Treatment Plan

43. Summary and Conclusion

44. Abbreviations

45. Abbreviations